Increased sales in all its geographic regions, including 7% growth in the firm’s key East Europe unit despite the ongoing conflict between Russia and Ukraine, pushed Krka’s Prescription Pharmaceuticals revenues up by 7% to €1.39bn ($1.50bn) in 2022.
Alongside the Czech Republic and Germany, Russia was among the highest growth geographic areas for Krka in the company’s largest...







